Cetera Trust Company N.A Acquires New Position in CareDx, Inc (NASDAQ:CDNA)

Cetera Trust Company N.A acquired a new stake in CareDx, Inc (NASDAQ:CDNA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 11,870 shares of the company’s stock, valued at approximately $142,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nisa Investment Advisors LLC raised its position in CareDx by 442.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,440 shares of the company’s stock worth $77,000 after buying an additional 5,253 shares during the last quarter. WINTON GROUP Ltd purchased a new position in CareDx during the 3rd quarter worth approximately $72,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in CareDx by 23.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,751 shares of the company’s stock worth $82,000 after buying an additional 2,211 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new position in CareDx during the 3rd quarter worth approximately $85,000. Finally, Principal Financial Group Inc. raised its position in CareDx by 14.3% during the 3rd quarter. Principal Financial Group Inc. now owns 17,635 shares of the company’s stock worth $123,000 after buying an additional 2,205 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, Stephens reissued an “overweight” rating and set a $15.00 price target on shares of CareDx in a research report on Wednesday, April 17th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, CareDx presently has an average rating of “Hold” and a consensus price target of $13.50.

CareDx Trading Down 1.7 %

CDNA opened at $8.17 on Tuesday. The firm has a market capitalization of $423.04 million, a PE ratio of -2.31 and a beta of 1.42. CareDx, Inc has a 12-month low of $4.80 and a 12-month high of $12.93. The firm has a 50 day moving average of $9.64 and a two-hundred day moving average of $9.21.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($2.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($1.97). The firm had revenue of $65.57 million for the quarter, compared to analyst estimates of $63.66 million. CareDx had a negative return on equity of 51.40% and a negative net margin of 67.88%. CareDx’s revenue for the quarter was down 20.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.34) EPS. As a group, analysts predict that CareDx, Inc will post -1.59 EPS for the current fiscal year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.